Cordant Inc’s Agios Pharmaceuticals AGIO Stock Holding History

Cordant Inc’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	–	–	90
2022 Q1	$0	Buy	+5	New	+$153	﹤0.01%	1212

Other funds holding AGIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Cordant Inc's AGIO Position: Q2 2022 in Review

Cordant Inc sold out of Agios Pharmaceuticals (AGIO) in Q2 2022, closing a stake of 5 shares.

Cordant Inc first reported a position in AGIO in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 155 funds tracked by Wall St. Rank hold AGIO as of Q2 2022.

Cordant Inc reported no remaining Agios Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Cordant Inc sold 5 Agios Pharmaceuticals shares in Q2 2022.
Cordant Inc first reported a position in Agios Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Cordant Inc's Agios Pharmaceuticals position peaked at $0 in Q1 2022.
155 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.